Skip to main content
. 2020 Feb 5;11(2):164. doi: 10.3390/genes11020164

Figure 2.

Figure 2

Mean expression values (delta-CT values) of miR-133b and miR-21 in different categories of CAD patients vs. control subjects: (a) Differential gene expression (delta-CT values) of miR-133b in different clinical categories of CAD Patients vs. Control subjects. A significant differential expression between control (12.98 ± 1.8; n = 50) and ACS (16.06 ± 1.5; n = 32); p-value < 0.0001, control vs. SA (14.74 ± 2.07; n = 28); p-value = 0.0002, control vs. NCA (14.05 ± 1.5; n = 15); p-value = 0.0446), NCA vs. ACS (p-value = 0.0001), SA vs. ACS (p-value = 0.0063) were obtained except NCA vs. SA (p-value = 0.2615); (b) Differential gene expression (delta-CT values) of miR-21 in different clinical categories of CAD patients vs. control subjects. A significant differential expression between control (6.23 ± 0.96; n = 54) and ACS (4.93 ± 0.64; n = 29); p value < 0.0001, control vs. SA (5.31 ± 0.65; n = 24); p value < 0.0001, NCA (6.06 ± 0.98; n = 8) vs. ACS (p-value < 0.0001), SA vs. ACS (p-value = 0.0410), NCA vs. SA (p-value < 0.0001) were obtained except control vs. NCA; p-value = 0.6522). Results were expressed as mean ± SD. One-way analysis of variance followed by Bonferroni correction for multiple comparisons was applied to assess the miRNA expression among controls and subcategories of CAD cases. p-value < 0.05 is considered to be significant.